Table 5: Incremental cost-effectiveness analyses:

evolocumab added to SoC vs SoC alone.

Scenarios

PHMD plus history

of MI or IS

HeFH

Δ Cost

Δ LY

ICER

Δ Cost

Δ LY

ICER

Base-case

$554,560

1.59

$348,629

$683,660

2.29

$298,148

5% increase

in EVO price

$582,237

1.59

$366,029

$719,364

2.29

$313,719

5% decrease

in EVO price

$526,883

1.59

$331,230

$647,956

2.29

$282,578

High discount rates*

$474,304

1.26

$376,837

$560,506

1.70

$329,364

Low discount rates‡

$661,415

3.15

$209,861

$860,832

5.58

$154,371

Use of

CTTC rate ratios§

$474,681

1.23

$384,626

$567,491

1.83

$310,261

SoC = standard of care;

PHMD = primary hypercholesterolemia and mixed dyslipidemia;

HeFH = heterozygous familial hypercholesterolemia;

LY = life years;

ICER = incremental cost-effectiveness ratio;

EVO = evolocumab.

The symbol Δ denotes incremental.

* An annual rate of 7% for both costs and LY.32

‡ Annual rates of 3% and 0% (i.e., undiscounted) for costs and LY,32 respectively.

§ 0.73 (myocardial infarction), 0.79 (ischemic stroke), and 0.86 (cardiovascular death) per 1 mmol/L of low-density lipoprotein cholesterol reduction.21 Note: All costs and ICER values are expressed in Mexican pesos.